SCHEMBL30206019

SCHEMBL30206019

CNc1nc(Nc2ccc(N3CCOCC3)c(C)c2)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 3/20 0.41
▸ EML4 Q9HC35 7/20 0.39
▸ ALK Q9UM73 7/20 0.39
▸ RET P07949 6/20 0.39
▸ ROS1 P08922 6/20 0.39
▸ FLT3 P36888 6/20 0.39
▸ MAPK9 P45984 5/20 0.39
▸ MAPK10 P53779 5/20 0.39
▸ P2RX3 P56373 2/20 0.36
▸ PKMYT1 Q99640 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ MAPK8 P45983 2/20 0.35
▸ BMPR1B O00238 1/20 0.35
▸ PLK4 O00444 1/20 0.35
▸ CIT O14578 1/20 0.35
▸ AURKA O14965 1/20 0.35
▸ GAK O14976 1/20 0.35
▸ EPHB6 O15197 1/20 0.35
▸ RIPK2 O43353 1/20 0.35
▸ BUB1 O43683 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173329 1.00 SYK (0.41) SYKEML4ALKRETROS1
SCHEMBL29173341 0.93 ALK (0.44) SYKEML4ALKRETROS1
SCHEMBL30206110 0.93 ALK (0.44) SYKEML4ALKRETROS1
SCHEMBL24944157 0.92 EML4 (0.47) SYKEML4ALKRETROS1
SCHEMBL30205760 0.92 EML4 (0.47) SYKEML4ALKRETROS1
SCHEMBL29173387 0.91 LRRK2 (0.40) SYKEML4ALKRETROS1
SCHEMBL30206045 0.91 FLT3 (0.37) SYKEML4ALKRETROS1
SCHEMBL29173438 0.91 FLT3 (0.37) SYKEML4ALKRETROS1
SCHEMBL30206049 0.91 LRRK2 (0.40) SYKEML4ALKRETROS1
SCHEMBL29173547 0.90 MEN1 (0.34) SYKPKMYT1MAPTBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 SYK 2532/4885EML4 2189/4885ALK 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback